License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2022 USD ($) performance_obligation	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 48,964	$ 48,756		$ 237,422	$ 153,973
Deferred revenue	44,561			44,561
Short-term deferred revenue	1,265			1,265		$ 20,906
Deferred revenue, net of current portion	43,296			43,296		21,474
Prepaid expenses and other current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable	5,609	3,442		5,609	3,442	4,309	$ 1,722
Accounts payable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue	0	0		0	0	3,171	$ 7,227
License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	6,725	12,003		$ 110,032	53,853
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation				3
Reimbursement of costs			$ 200
Estimated current global development costs subsequent to March 31, 2017				$ 216,700
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Prepaid expenses and other current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable						1,300
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Accounts payable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue						$ 900
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue	$ 0	$ 1,860		5,503	$ 13,532
Otsuka Pharmaceutical Company. Ltd. | Up Front Non Refundable And Non Creditable | Otsuka International Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received				$ 73,000